Abstract: This invention provides fusion proteins comprising a Filovirus glycoprotein segment and an immunoglobulin polypeptide segment. The fusion proteins are useful in immunogenic compositions to protect against infections by Filoviruses, such as Ebola virus, in both humans and non-human animals. The fusion proteins are also useful in diagnostic assays to detect Filovirus infections.
Type:
Grant
Filed:
October 28, 2011
Date of Patent:
May 24, 2016
Assignee:
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
Inventors:
Gerardo Kaplan, Krishnamurthy Konduru, Jerome Jacques, Sina Bavari, Steven Bradfute
Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.
Type:
Grant
Filed:
October 1, 2013
Date of Patent:
May 10, 2016
Assignees:
Innate Pharma S.A.S., Novo Norkisk A/S
Inventors:
Peter Andreas Nicolai Reumert Wagtmann, Francois Romagne, Joakim Glamann
Abstract: The invention provides methods, compositions and kits for treating and or preventing an HIV infection. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to the HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS).
Abstract: Described herein is a soluble HIV-1 retrovirus transmembrane glycoprotein gp41 trimer (Soc-gp41M-Fd) containing a partial ectodomain and the cytoplasmic domain, that is fused to the small outer capsid (Soc) protein of bacteriophage T4 and the Foldon domain of the bacteriophage T4 fibritin (Fd). The gp41 trimer that has a prehairpin structure could be utilized to understand the mechanism of viral entry and as a candidate for development of HIV-1 vaccines, diagnostics and therapeutics. Other secondary embodiments of the gp41 proteins containing different modifications are also disclosed. According to one embodiment, the gp41 trimer is further attached to a cell penetration peptide (CPP). Methods of producing gp41 trimers are also disclosed.
Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.
Type:
Grant
Filed:
September 25, 2012
Date of Patent:
April 26, 2016
Assignee:
Trellis RSV Holdings, Inc.
Inventors:
Lawrence M. Kauvar, Ellen J. Collarini, Bruce Keyt, Orit Foord
Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
Type:
Grant
Filed:
January 31, 2011
Date of Patent:
April 19, 2016
Assignee:
The United States of America as rep. by the Sec'y of the Army, for U.S. Army Medical Research Institute of Infectious Diseases
Abstract: Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions.
Type:
Grant
Filed:
November 25, 2013
Date of Patent:
February 23, 2016
Assignee:
The United States of America, as Represented by the Secretary, Department of Health and Human Services
Abstract: Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also effective for HSV and HPV infection. Also disclosed are novel viral attachment inhibitors and methods of use.
Type:
Grant
Filed:
March 9, 2015
Date of Patent:
February 16, 2016
Assignee:
The Johns Hopkins University
Inventors:
Ru Chih C. Huang, Ibrahim S. Abd-Elazem
Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.
Type:
Grant
Filed:
December 16, 2014
Date of Patent:
December 22, 2015
Assignees:
The United States of America as represented by the Secretary of the Department of Health and Human Services, Istituto Superiore di Sanita
Inventors:
Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
Abstract: A sensor chip for detecting an immune response against an influenza virus, the sensor chip including a substrate having a surface and a plurality of hemagglutinin polypeptides bound to discrete locations on the surface of the substrate, each hemagglutinin polypeptide having a hemagglutinin epitope. Detection devices containing the sensor chip and methods of detecting influenza immune responses are also described herein.
Type:
Grant
Filed:
July 11, 2013
Date of Patent:
December 22, 2015
Assignee:
University of Rochester
Inventors:
Benjamin L. Miller, Tim R. Mosmann, David Topham, Charles R. Mace
Abstract: The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein or a human immunodeficiency virus (HIV).
Type:
Grant
Filed:
March 2, 2007
Date of Patent:
December 22, 2015
Assignees:
MYMETICS CORPORATION, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), PEVION BIOTECH LTD.
Abstract: Disclosed is a method for treatment of HIV related diseases comprising targeting complexes between on the one hand the C5 domain of gp120 and on the other hand gp41 or the C2 domain of gp120. The complexes may be stabilised by administering compounds, such as antibodies, capable of directly interacting with and stabilising the complex, or by immunizing with C5 and gp41/C2 derived material so as to induce antibodies that bind to and stabilise the complex.
Type:
Grant
Filed:
July 3, 2010
Date of Patent:
December 1, 2015
Assignee:
Bionor Immuno AS
Inventors:
Maja Sommerfelt Grønvold, Angus Dalgleish, Einar Tønnes Lange, Jens Olof Holmberg, Per Bengtsson, Birger Sørensen
Abstract: The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.
Type:
Grant
Filed:
October 27, 2011
Date of Patent:
December 1, 2015
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Beth-Ann Griswold Coller, Vidya B. Pai, D. Elliot Parks, Michele Yelmene, Andrew J. Bett, Timothy Martyak
Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
Type:
Grant
Filed:
March 11, 2014
Date of Patent:
November 17, 2015
Assignee:
Altravax, Inc.
Inventors:
Doris Apt, Juha Punnonen, Alice M. Brinkman
Abstract: The compositions and methods described herein relate to lentiviral vectors that can be used to generate virions/viruses that exhibit enhanced infectivity with respect to monocyte-derived macrophages (MDM) and dendritic cells (MDDC). Such compositions and methods further relate to production of virions/viruses that can be used as components of vaccines that effectively stimulate innate immune responses. In a particular embodiment, compositions and methods described herein relate to production of virions/viruses that can be used as components of human immunodeficiency-1 (HIV-1) vaccines administered to stimulate innate immune responses to HIV-1.
Type:
Grant
Filed:
January 17, 2013
Date of Patent:
October 6, 2015
Assignee:
New York University
Inventors:
Nathaniel R. Landau, Nicole Sunseri, Thomas D. Norton
Abstract: Certain embodiments of the invention are directed to methods and compositions comprising a Rift Valley fever virus (RVFV) wherein a heterologous nucleic acid encoding a dsRNA-dependent protein kinase (PKR) inhibitor is inserted into the NSs region of the virus.
Type:
Grant
Filed:
February 14, 2013
Date of Patent:
September 29, 2015
Assignee:
The Board of Regents of the University of Texas System
Inventors:
Tetsuro Ikegami, Birte Kalveram, Sabarish Indran, Olga Lihoradova, Alexander Freiberg
Abstract: The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine.
Type:
Grant
Filed:
August 24, 2007
Date of Patent:
September 15, 2015
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Bernard Moss, Linda Wyatt, Patricia Earl
Abstract: This invention concerns methods for detecting the presence of an anti-HIV-1 antibody in a biological sample, the method comprising conducting an immunoassay comprising: (a) contacting the biological sample with at least one epitope that is recognized by the anti-HIV-1 antibody, wherein the contacting being under conditions sufficient to permit the anti-HIV-1 antibody if present in the sample to bind to the epitope and form an epitope-anti-HIV-1 antibody complex; (b) contacting the formed epitope-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule, the contacting being under conditions sufficient to permit the anti- HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of the formed epitope-anti-HIV-1 antibody complex and form an extended complex; and (c) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample by determining the presence or concentration of the formed extended complex; the epitope being present on a peptide comprising SEQ ID N
Type:
Grant
Filed:
December 23, 2010
Date of Patent:
September 1, 2015
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
Type:
Grant
Filed:
October 9, 2012
Date of Patent:
August 25, 2015
Assignee:
ABBOTT LABORATORIES
Inventors:
Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner